IP Library Granted Patent US 12,377,046
Granted Patent B1
US 12,377,046 · App. 16/857,865 · Granted Aug 5, 2025

Delivery system matrices

Inventor: Mark J. Neveu (Bethel, ME)
Assignee: Wellomics LLC
A61K9/107A23B20/10A23D7/0053A23D7/04A23L29/231A23L29/25A23L33/105A23L33/125A23L33/22A61K9/06A61K47/36A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,046
App. No.
16/857,865
Granted
Aug 5, 2025
Kind
B1
Abstract

This invention relates to delivery matrix compositions (e.g., dietary products or pharmaceuticals) and related methods. In particular, the disclosure relates to delivery matrix compositions that include temperature-dependent O/W emulsion complexes, low viscosity sheared fluid gels, and viscous hydrogels that can facilitate the delivery of a wide range of substances to the gastrointestinal tract (e.g., small intestine) of a subject.

Claims (36)

1. A dietary product or oral pharmaceutical comprising an oil-in-water (O/W) emulsion complex comprising a water phase and an oil phase, ascorbyl palmitate, a high hydrophile-lipophile balance (HLB) saponin with a HLB of greater than or equal to 10, and a Glycyrrhiza glabra (licorice) root saponin, wherein the concentration of ascorbyl palmitate is 0.15-4.5 mg/gm, wherein the concentration of the high HLB saponin is 0.01-1.6 mg/gm, and wherein the concentration of Glycyrrhiza glabra root saponin is 0.02-160 mg/gm.

2. The dietary product or oral pharmaceutical of claim 1 , wherein the high HLB saponin is a Quillaja saponaria saponin.

3. The dietary product or oral pharmaceutical of claim 1 , wherein the high HLB saponin is a Yucca saponin.

4. The dietary product or oral pharmaceutical of claim 1 , wherein the high HLB saponin is from tea seeds, bitter melon Momordica charantia, Panax ginseng , fenugreek Trigonella Foenum graecum , alfalfa root Medicago sativa , Siberian ginseng Eleuthrerococcus senticosus, Astragalus membranaceus, Bacopa monniera, Nigella sativa, Aralia mandshurica, Beyonia alba, Rhaponticum carthamoides, Gymnema sylvestre, Gynostemma pentaphyllum, Withania somnifera, Tinaspora cordifolia , Milkwort Polygala, Simlax officinalis , or Aesculis hipocastanum.

5. The dietary product or oral pharmaceutical of claim 1 , wherein the Glycyrrhiza glabra (licorice) root saponin is monoammonium glycyrrhizinate, ammoniated glycyrrhizin, or glycyrrhizic acid.

6. The dietary product or oral pharmaceutical of claim 1 , wherein the oil phase comprises an edible oil.

7. The dietary product or oral pharmaceutical of claim 1 , wherein the O/W emulsion complex further comprises a stabilizing hydrophilic agent, wherein the stabilizing hydrophilic agent is a cyclodextrin, maltodextrin, beta glucan, dietary fiber, natural emulsifier protein, or cationic carrier.

8. The dietary product or oral pharmaceutical of claim 1 , wherein the O/W emulsion complex further comprises a compound that increases bioavailability, wherein the compound that increases bioavailability is a fructooligosaccharide, dietary fiber, mucilaginous extract, hydrocolloid, quercetin, ginger, genistein, naringin, sinomenine, piperine, nitrile glycoside, beta glucan, or chitosan.

9. The dietary product or oral pharmaceutical of claim 1 , wherein the O/W emulsion complex further comprises a viscosity modifier, a humectant, mucilaginous ingredient, plant extract, dietary fiber, protein, cyclodextrin, pectin, polyethylene glycol, propylene glycol, alcohol, cold set plant extract, agar, starch, cellulose gum, locust bean gum, hydrocolloid, polyvinylpyrrolidone, poloxamer 488, carboxymethylcellulose, gum acacia, or beta glucan.

10. A dietary product or oral pharmaceutical comprising a gel delivery matrix comprising:

(a) an O/W emulsion complex that is thixotropic with a glass-transition temperature range between 50-80° C.;

(b) a pectin with 10-40% ester groups; and

(c) a cation,

wherein the concentration of pectin is 1-10 mg/gm or.

11. A dietary product or oral pharmaceutical comprising a hydrogel delivery matrix comprising:

(a) gel delivery matrix or an O/W emulsion complex that is thixotropic with a glass-transition temperature range between 50-80° C.;

(b) at least one beta glucan; and

(1) any one or more of acacia gum, a hydrocolloid, and a molecule that reduces syneresis and increases viscosity; and/or

(2) a fructooligosaccharide and/or mucilaginous extract, hydrocolloid, or dietary fiber;

wherein the molecule that reduces syneresis and increases viscosity is a plant extract, dietary fiber, protein, cyclodextrin, beet pectin or high methoxy calcium insensitive pectin, or cold set plant extract, and

wherein the concentration of the beta glucan is 2-30 mg/gm.

12. The dietary product or oral pharmaceutical of claim 1 , wherein the O/W emulsion complex has a glass-transition temperature range between 50-80° C.

13. The dietary product or oral pharmaceutical of claim 1 , wherein the O/W emulsion complex further comprises a dietary agent.

14. The dietary product or oral pharmaceutical of claim 1 , wherein the O/W emulsion complex further comprises a pharmaceutical agent.

15. The dietary product or oral pharmaceutical of claim 10 , wherein the pectin is an amidated pectin.

16. The dietary product or oral pharmaceutical of claim 10 , wherein the pectin comprises the structure as shown in FIG. 1 :

17. The dietary product or oral pharmaceutical of claim 10 , wherein the cation is a divalent cation.

18. The dietary product or oral pharmaceutical of claim 17 , wherein the divalent cation is a Calcium, Zinc, Magnesium or Manganese divalent cation.

19. The dietary product or oral pharmaceutical of claim 10 , wherein the gel delivery matrix has a viscosity of 50-50,000 cps.

20. The dietary product or oral pharmaceutical of claim 11 , wherein the hydrogel delivery matrix comprises acacia gum, and wherein the concentration of the acacia gum is 2-30 mg/gm.

21. The dietary product or oral pharmaceutical of claim 11 , wherein the hydrogel delivery matrix has a viscosity of 10,000 to 100,000 cps.

22. The dietary product or oral pharmaceutical of claim 11 , wherein the gel delivery matrix is the gel delivery matrix of claim 10 .

23. The dietary product or oral pharmaceutical of claim 10 , wherein the concentration of pectin is 1.5-5 mg/gm.

24. The dietary product or oral pharmaceutical of claim 10 , wherein the O/W emulsion complex is the O/W emulsion complex of claim 1 .

25. The dietary product or oral pharmaceutical of claim 10 , wherein the pectin is citrus peel pectin.

26. The dietary product or oral pharmaceutical of claim 10 , wherein the pectin is apple pectin.

Assignments (2)
SECURITY INTEREST Recorded Jan 8, 2026
From: LIFE SCIENCE INSTITUTE, LLC
To: TRAILBLAZE HOLDINGS LLC
Reel/Frame 073412/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2025
From: NEVEU, MARK J
To: WELLOMICS LLC
Reel/Frame 071122/0335 →
Continuity (1)
Provisional Application 62838260 · Apr 24, 2019
References Cited (9)
US 5630796A · Bellhouse et al. · 1997 [cited by applicant]
JP 6836825B2 · 2021 [cited by applicant]
WO WO2013149323A1 · 2013 [cited by examiner]
WO WO2017009480A1 · 2017 [cited by applicant]
Maier et al., Food Hydrocolloids, 2016, 57, 221-228. [cited by examiner]
Chan et al, Carbohydrate Polymers, 2017, 161, 118-139. [cited by examiner]
Mayuree et al, Polysaccharides, 2015, pp. 1867-1892, Springer International Publishing. [cited by examiner]
Abel et al., Stimulation of human monocyte beta-glucan receptors by glucan particles induces production of TNF-alpha and IL-1 beta. Int J Immunopharmacol. Nov. 1992;14(8):1363-73. doi: 10.1016/0192-0561(92)90007-8. [cited by applicant]
Yu et al., Tunable glycyrrhizic acid supramolecular hydrogels via metal ion complexation. Giant. 2024; 17: 1-15. https://doi.org/10.1016/j.giant.2024.100240. [cited by applicant]